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Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from
cutaneous T cell lymphoma
Aims: Histopathological overlap between lupus erythe-
matosus and certain types of cutaneous T cell lymphoma
(CTCL) is well documented. CD123+ plasmacytoid den-
dritic cells (PDCs) are typically increased in lupus erythe-
matosus, but have not been well studied in CTCL. We
aimed to compare CD123 immunostaining and
histopathological features in these conditions.
Methods and results: Skin biopsies of cutaneous lupus
erythematosus (CLE, n = 18), lupus erythematosus
panniculitis (LEP, n = 17), mycosis fungoides (MF,
n = 25) and subcutaneous panniculitis-like T cell
lymphoma (SPTCL, n = 9) were retrospectively
reviewed and immunostained with CD123. Percent-
age, distribution and clustering of CD123+ cells were
compared between CLE and MF and between LEP and
SPTCL using v2 and two-tailed t-tests. A higher per-
centage of CD123+ cells was observed in CLE than
MF (P < 0.01), more frequently comprising ≥20% of
the entire infiltrate (P < 0.01) and forming clusters
(P < 0.01). Similarly, LEP showed a higher percent-
age of CD123+ cells than SPTCL (P = 0.01), more fre-
quently comprising ≥20% of the infiltrate (P = 0.04)
and forming clusters (P = 0.01). Basal vacuolar
change or dyskeratosis was observed in all CLE cases
and in 48% cases of MF cases (P = 0.05). Plasma
cells were readily identified in 76% cases of LEP but
in none of the SPTCL cases (P = 0.01). Adipocyte
rimming by lymphocytes, hyaline fat necrosis and fib-
rinoid/grungy necrosis did not significantly differ
between LEP and SPTCL. Dermal mucin also failed to
distinguish between groups.
Conclusions: CD123 immunostaining is helpful in dif-
ferentiating CLE from MF and LEP from SPTCL, but
should be interpreted in conjunction with clinico-
pathological features and other ancillary studies to
ensure accurate diagnosis.
Keywords: CD123, cutaneous T cell lymphoma, lupus erythematosus, mycosis fungoides, plasmacytoid dendritic
cells, subcutaneous panniculitis-like T cell lymphoma
Introduction
Histopathological overlap between cutaneous/subcu-
taneous lupus erythematosus and cutaneous T cell
lymphoma (CTCL) is well recognised, and may
present a diagnostic challenge. Although mycosis
fungoides (MF) is readily diagnosed when fully devel-
oped, classic features such as Pautrier microabscesses
are often lacking in early cases.1–3 Such cases may
mimic various inflammatory dermatoses such as
eczematous dermatitis, connective tissue disease, pig-
mented purpuric dermatosis and lichen sclerosus.4–6
Of these, cutaneous lupus erythematosus (CLE) may
enter the differential diagnosis of MF when interface
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changes1–3,7–10 or dyskeratotic keratinocytes2,3,8 are
present. Conversely, some cases of CLE may show a
robust lymphomatoid infiltrate at the dermo-epider-
mal junction and around blood vessels, potentially
raising concern for MF.6,10,11
Even more notoriously challenging is the distinc-
tion between lupus erythematosus panniculitis (LEP)
and subcutaneous panniculitis-like T cell lymphoma
(SPTCL).12–19 Several authors have reported misdiag-
nosis of LEP as SPTCL and vice versa.14,15,20,21
Specifically, interface changes and other classic fea-
tures of LEP have been reported in SPTCL.13,18,22,23
The striking similarities of LEP and SPTCL have led
some authors to propose that these entities may
belong on a spectrum of T cell dyscrasia.12,16 A Euro-
pean Organisation for Research and Treatment of
Cancer study group reported that 19% of the patients
with SPTCL had an associated autoimmune disease,
with one-third of those having systemic lupus erythe-
matosus.15 These findings further support a possible
link between LEP and SPTCL.
Plasmacytoid dendritic cells (PDCs), most com-
monly stained with CD123, are rarely present in
normal skin.24–26 The distribution and quantification
of CD123+ PDCs have been studied in a variety of
inflammatory dermatoses.18,26–33 Increased density
and clustering of PDCs have been noted in all forms
of lupus erythematosus,24,26,30,31,34,35 including
LEP.18,19,36 In contrast, their density and distribu-
tion have been less rigorously studied in CTCL. Only
three prior studies have examined PDCs in SPTCL,
all of which found PDC clusters in significantly
fewer cases of SPTCL than in LEP.18,29,37 Another
two studies have utilised the BDCA2/CD303
antibody to detect PDCs, in addition to other den-
dritic cell types, in various stages of MF and Sezary
syndrome.38,39
The goal of this study was to compare CD123
immunostaining and various histopathological fea-
tures in lupus erythematosus (CLE and LEP) and
CTCL (MF and SPTCL).
Materials and methods
After approval by the Institutional Review Board, the
pathology database at University of Michigan was
searched for skin biopsies diagnosed as CLE (discoid,
subacute cutaneous or systemic), LEP, MF and SPTCL
between 2000 and 2017. An additional case of
SPTCL was obtained from Tufts Medical Center. All
cases were diagnosed originally based on clinico-
pathological correlation, with supporting
immunohistochemical and T cell receptor (TCR) gene
rearrangement studies as needed. Clinical data were
obtained from electronic medical records.
Haematoxylin and eosin (H&E)-stained sections of
CLE and MF cases were evaluated for the following
features: basal vacuolation with associated lympho-
cytes and/or dyskeratotic keratinocytes, Pautrier
microabscesses, melanin incontinence, increased der-
mal mucin and readily identifiable plasma cells. For
LEP and SPTCL the following were evaluated: basal
vacuolation with associated lymphocytes and/or
dyskeratotic keratinocytes, increased dermal mucin,
adipocyte ‘rimming’ by lymphocytes, readily identifi-
able plasma cells, hyaline fat necrosis and fibrinoid/
grungy fat necrosis (fibrinoid necrosis containing
karyorrhectic debris).
CD123 immunohistochemistry was performed on
all cases. The majority of cases were immunostained
at the University of Michigan research laboratory
using the following protocol: 4-lm thick sections
were deparaffinised and heat-induced epitope retrie-
val was performed using the Dako PT Link with a
proprietary Tris-ethylenediamine tetraacetic acid
(EDTA) buffer pH 9 from Dako (Carpenteria, CA,
USA; FLEX retrieval solution, high pH). After block-
ing endogenous peroxidase activity, the slides were
incubated for 120 min at room temperature with a
mouse monoclonal CD123 antibody (7G3; BD
Pharmingen, Franklin Lakes, NJ, USA) and subse-
quently detected on the EnVision FLEX+ mouse
diaminobenzidine (DAB) detection system (Dako). A
small subset of cases was immunostained at the time
of original diagnosis using the same antibody on the
BenchMark ULTRA slide staining platform (Ventana
Medical Systems, Tucson, AZ, USA), according to
standard protocols validated in our clinical immuno-
histochemistry laboratory. Protein expression was
detected using the ultraView Universal DAB Detec-
tion Kit (Ventana).
Plasmacytoid dendritic cells were identified by
strong and crisp CD123 staining of small, round to
oval cells outside of blood vessels. The percentage of
CD123+ PDCs of the entire infiltrate was assessed
semiquantitatively from 0 to 100%. Clusters of
CD123+ PDCs were defined as tight aggregates of
≥15 CD123+ PDCs. Subcutaneous location of PDC
clusters and intra-epidermal PDCs were additionally
recorded. Other immunohistochemical findings were
recorded from the original pathology reports.
Histopathological and CD123 immunohistochemi-
cal findings were compared between groups: CLE
versus MF and LEP versus SPTCL; v2 and two-tailed
t-tests were used for categorical and continuous data,
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 908–916.
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respectively. A P ≤ 0.05 was considered statistically
significant.
Results
Eighteen CLE biopsies from 18 patients, 25 MF biop-
sies from 23 patients, 17 LEP biopsies from 14
patients and nine SPTCL biopsies from nine patients
were identified. Patients with CTCL (mean
age = 66 years) were generally older than those with
lupus erythematosus (mean = 45 years) (P < 0.01).
Female predominance was observed in the lupus
group (male-to-female ratio = 1:2.5), whereas the
reverse was seen the CTCL group (male-to-female
ratio = 2:1). Antinuclear antibody serologies were
available in a subset of cases and were positive in
nine of 11 CLE patients, nine of 12 LEP patients,
none of three MF patients and one of two SPTCL
patients. Follow-up data were available for eight CLE
patients and 11 LEP patients, none of whom devel-
oped lymphoma over a mean follow-up period of 4
and 5 years, respectively.
The histopathological and immunohistochemical
findings in CLE and MF are summarised in Table 1.
Basal vacuolar changes and/or dyskeratotic cells were
more frequently seen in CLE than in MF (P = 0.05)
(Figure 1A,B). Pautrier microabscesses were found
exclusively in MF (P < 0.01). Increased dermal
mucin, melanin incontinence and plasma cells did
not show significant differences between these groups.
The mean percentage of CD123+ PDCs was higher in
CLE (21%; Figure 1C) than in MF (4%; Figure 1D)
(P < 0.01). These cells more frequently comprised
≥20% of the entire infiltrate (P < 0.01) and formed
clusters (P < 0.01) in CLE (Figure 1E) compared to
MF (Figure 1F). Intra-epidermal CD123+ PDCs were
common in both groups.
The histopathological and immunohistochemical
findings in LEP and SPTCL are summarised in
Table 2. Plasma cells were readily identified only in
LEP (Figure 2A) and not in SPTCL (Figure 2B)
(P = 0.01). All other examined histopathological fea-
tures failed to distinguish between groups (Figure 2C,
D). The mean percentage of CD123+ PDCs was signif-
icantly higher in LEP (17%) than in SPTCL (2%)
(P = 0.01). Approximately half the LEP cases con-
sisted of ≥20% CD123+ PDCs (Figure 2E), while none
of the SPTCL cases did (Figure 2F) (P = 0.04). The
majority of LEP cases contained clusters of PDCs (Fig-
ure 2G), which was consistently absent in SPTCL
(Figure 2H) (P = 0.01). Intra-epidermal CD123+ cells
were similarly common in both groups. Non-specific,
weak and ‘fluffy’ CD123 staining was noted in the
subcutaneous fat in both LEP and SPTCL cases with
significant fat necrosis (Figure 3). Such staining
appeared to be located in histiocytes and/or extracel-
lular matrix.
Additional immunohistochemical stains were per-
formed on two CLE cases, seven LEP cases and all
CTCL cases at the time of diagnosis. All examined
lupus cases showed a normal T cell immunopheno-
type, except for one LEP case. This latter case dis-
played a reversed CD4:CD8 ratio (1:3) but otherwise
classic histomorphological features of LEP including
vacuolar interface changes, hyaline fat necrosis,
increased dermal mucin and increased plasma cells.
All MF and SPTCL cases revealed aberrant T cell
immunophenotypes.
Results of TCR gene rearrangement studies (per-
formed at the time of diagnosis) were available for a
subset of MF, LEP and SPTCL cases. A T cell clone was
identified in four of five (80%) MF cases, none of five
(0%) LEP cases and four of four (100%) SPTCL cases.
Discussion
Although most cases of CLE are readily distinguish-
able from MF, this differential diagnosis can be
Table 1. Comparison of clinical, histopathological and
immunohistochemical (CD123) findings in cutaneous lupus
erythematosus (CLE) and mycosis fungoides (MF)
CLE (n = 18) MF (n = 25) P-value
Mean age (years) 47 70 <0.01
Male-to-female ratio 1:2.6 3:1 0.04
Basal vacuolar changes
or dyskeratosis
18 (100%) 12 (48%) 0.05
Pautrier microabscesses 0 (0%) 12 (48%) <0.01
Increased dermal mucin 13 (72%) 8 (32%) 0.06
Melanin incontinence 11 (61%) 6 (24%) 0.06
Readily identifiable
plasma cells
7 (39%) 6 (24%) 0.37
Mean % CD123+ cells 21% 4% <0.01
≥20% CD123+ cells 12 (67%) 3 (12%) <0.01
Intra-epidermal
CD123+ cells
18 (100%) 19 (76%) 0.40
CD123+ cluster(s) 17 (94%) 0 (0%) <0.01
Bold type indicates statistical significance.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 908–916.
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challenging at times. For example, mild basal vacuo-
lar changes and occasional dyskeratotic keratinocytes
in MF may raise consideration for CLE, whereas CLE
with a robust lymphocytic infiltrate at the dermo-epi-
dermal junction may simulate epidermotropism in
MF. Similarly, histopathological overlap between LEP
and SPTCL is well recognised,12–14,16–19,22,23,29 and
has led to a proposed spectrum of subcutaneous T cell
dyscrasia encompassing both entities. As distinction
between cutaneous/subcutaneous lupus erythemato-
sus and CTCL is crucial for guiding appropriate clini-
cal work-up and treatment, we aimed to assess the
utility of the CD123 immunostain in addition to vari-
ous histopathological features in differentiating these
entities.
Plasmacytoid dendritic cells are a subtype of den-
dritic cells that produce type I interferons (alpha/
beta). These cells can be highlighted by immunohisto-
chemistry for CD123 (interleukin-3 receptor a chain)
or BDCA-2/CD303. The quantity and distribution of
PDCs vary in different inflammatory and neoplastic
conditions. Increased number and clustering of
PDCs have been described as common findings in
CLE24,26–28,30,31,34,35 and LEP,18,29 and these cells
A B
C D
E F
Figure 1. Selected histopathological features and CD123 immunostaining in cutaneous lupus erythematosus (CLE) and mycosis fungoides
(MF). (A) An example of CLE shows an interface dermatitis with aggregates of lymphocytes at the dermo-epidermal junction (H&E) (B) An
example of MF shows lymphocyte tagging and mild vacuolation of the basal layer (H&E). (C,E) This case of CLE demonstrates many CD123+
plasmacytoid dendritic cells (PDCs) constituting 30% of the entire inflammatory cell infiltrate and forming prominent clusters. (D,F) This
example of MF shows fewer CD123+ PDCs constituting 10% of the entire infiltrate without clustering.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 908–916.
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are thought to play an important role in the patho-
genesis of lupus erythematosus.26
Only two previous studies have assessed the quan-
tity and distribution of PDCs in MF, neither of which
has compared their results with CLE or other inflam-
matory dermatoses.28,39 Schwingshackl et al. noted
an increased number of single and loosely aggregated
PDCs in MF compared with normal skin, and con-
cluded that their number was dependent on the
intensity of the infiltrate.38 Pileri et al. also observed
rare loose aggregates of PDCs in MF, and that their
number was significantly higher in stage IIB com-
pared to stage IA/B disease.39 While these results
offered insight into the microenvironment of MF, the
utility of CD123+ PDCs in distinguishing MF from
CLE remained to be investigated.
Of all histopathological parameters compared
between CLE and MF, basal vacuolar changes and
dyskeratotic cells were of particular interest given
their potential to masquerade MF as an interface der-
matitis.6,8,9 In our cohort, although these changes
were more frequently seen in CLE, the difference
barely reached statistical significance (P = 0.05). The
specificity of these changes was poor (52%), as almost
half of our MF cases showed these features. Other ser-
ies have reported interface changes in 59–76% of MF
cases.2,3 These findings should caution pathologists
against using basal vacuolation and dyskeratotic ker-
atinocytes alone to exclude a diagnosis of MF.
Although the presence of Pautrier microabscesses
was highly specific (100%) for MF, its sensitivity was
low (48%). This is in keeping with previous reports of
Pautrier microabscesses in fewer than half of MF
cases.2,3,7,40 Plasma cells are commonly present in
connective tissue diseases, including lupus erythe-
matosus. Although less well described in MF, plasma
cells have been reported in 9% of MF/Sezary syn-
drome cases.41 We found a modest amount of plasma
cells in 24% of our MF cases, where they were readily
identified and failed to distinguish between CLE and
MF. Lastly, both increased dermal mucin and melanin
incontinence (a common consequence of interface
dermatitis) were slightly more common in CLE, but
the associations fell short of statistical significance
(P = 0.06). Together, these findings indicate that
histopathological distinction between CLE and MF has
its limitations, and ancillary tools are needed in chal-
lenging cases.
The percentage of PDCs and their tendency to form
clusters in our CLE cases was similar to that reported
previously.28,30,31,35 We found that a cut-off of 20%
PDCs separated CLE and MF reasonably well. Further-
more, presence of PDC cluster(s) was both highly sen-
sitive (94%) and specific (100%) for the diagnosis of
CLE when compared with MF, rendering CD123 a
superior diagnostic tool in distinguishing these condi-
tions. The percentage of CLE cases with intra-epider-
mal CD123+ cells (100%) was higher than reported
previously,35 yet this feature was also common in MF
and thus was not helpful.
With regard to the comparison between LEP and
SPTCL, the only reliable discriminative histopatholog-
ical feature in our study was the presence of readily
identifiable plasma cells, seen exclusively in LEP.
Other histopathological features deemed helpful in
previous studies failed to show significant differences
in ours. Hyaline fat necrosis was more common in
LEP, but was observed in fewer than half these cases.
Fibrinoid/grungy necrosis, previously reported to be
supportive of SPTCL,29 was seen at almost equal fre-
quency in both groups. Adipocyte rimming by
Table 2. Comparison of clinical, histopathological and
immunohistochemical (CD123) findings in lupus erythe-
matosus panniculitis (LEP) and subcutaneous panniculitis-
like T cell lymphoma (SPTCL)
LEP (n = 17) SPTCL (n = 9) P-value
Mean age (years) 43 54 0.20
Male-to-female ratio 1:2.4 1:1.3 0.65
Basal vacuolar changes
or dyskeratosis
10/16 (63%)a 2/7 (29%)a 0.29
Increased dermal mucin 12 (71%) 4/7 (57%)a 0.70
Adipocyte rimming by
lymphocytes
12 (71%) 8 (89%) 0.60
Readily identifiable
plasma cells
13 (76%) 0 (0%) 0.01
Hyaline fat necrosis 8 (47%) 1 (11%) 0.14
Fibrinoid/
grungy necrosis
5 (29%) 3 (33%) 0.88
Mean % CD123+ cells 17% 2% 0.01
≥20% CD123+ cells 8 (47%) 0 (0%) 0.04
Intra-epidermal
CD123+ cells
4/16 (25%)a 2/7 (29%)a 0.86
CD123+ cluster(s) in
any location
12 (71%) 0 (0%) 0.01
CD123+ cluster(s)
in fat
7 (41%) 0 (0%) 0.06
Bold type indicates statistical significance.
aAbsence of epidermis and/or dermis precluded evaluation of these
features in some cases.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 908–916.
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Figure 2. Selected histopathological features and CD123 immunostaining in lupus erythematosus panniculitis (LEP) and subcutaneous pan-
niculitis-like T cell lymphoma (SPTCL). (A) Plasma cells and adipocyte rimming by lymphocytes in a case of LEP. (B) A subcutaneous lym-
phoid infiltrate in SPTCL lacks plasma cells. (C) Fibrinoid/grungy necrosis in LEP. (D) Increased dermal mucin in a case of SPTCL. (E,G) An
example of LEP contains 40% CD123+ plasmacytoid dendritic cells (PDCs) with formation of several clusters, including some in the subcuta-
neous fat. (F,H) This case of SPTCL shows a few scattered CD123+ PDCs constituting less than 10% of the infiltrate, without formation of
clusters.
© 2018 John Wiley & Sons Ltd, Histopathology, 74, 908–916.
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atypical lymphocytes was another useful feature
according to previous reports.18,29 In our experience,
however, evaluation for lymphocytic atypia tends to
be subjective, as it was not uncommon to find slightly
hyperchromatic and irregular lymphocytes in LEP.
We therefore assessed for adipocyte rimming by lym-
phocytes regardless of the degree of atypia, and found
no association with either group. While the limited
utility of histopathological features in this differential
diagnosis may be attributable, in part, to the small
sample size of SPTCL in this cohort, our findings
again highlight a significant need for additional tools
to help distinguish these conditions.
The presence of PDCs has been examined in SPTCL
in comparison with LEP in three previous studies. All
these studies found that PDC clusters were more com-
mon in LEP, but were also present in a smaller subset
of SPTCL cases.18,29,37 This feature must therefore be
interpreted in the context of clinical, histopathologi-
cal, immunophenotypical and molecular findings. As
none of our SPTCL cases showed ≥20% PDCs or PDC
clusters, we consider these findings highly specific for
a diagnosis of LEP. Of note, we observed that cases
with fat necrosis tended to show weak, ‘fluffy’ CD123
staining of histiocytes and/or extracellular matrix in
the subcutis. Such non-specific staining could lead to
overinterpretation of PDC clusters. Recognition of the
strong and crisp staining of true PDCs, which are typ-
ically small and round to oval in shape, would avoid
this pitfall. Also, a strict requirement of ≥15 touching
CD123+ PDCs in a PDC cluster will probably improve
the specificity of this finding.
Interestingly, one LEP case demonstrated a reversed
CD4:CD8 ratio. While this case was classified as LEP
based on a history of systemic lupus erythematosus
and classic histopathological features, CD123+ PDCs
were notably absent. We therefore speculate that the
loss of PDCs could represent an early sign of progres-
sion on the LEP-SPTCL spectrum. Unfortunately, this
patient was lost to follow-up a year after the biopsy,
precluding further assessment.
A major limitation of this study is the small sample
size, especially of the SPTCL group, due to relative
rarity of this condition and over-representation of
consult cases from outside facilities (hence limited
access to tissue blocks). Another limitation is that
only a small subset of cases has been studied by TCR
gene rearrangement at the time of diagnosis; how-
ever, lack of evidence of progression to lymphoma in
patients diagnosed with CLE and LEP provided addi-
tional support for their diagnoses.
In conclusion, our study confirms that the CD123
immunostain is a useful ancillary tool in differentiat-
ing CLE from MF and LEP from SPTCL. In particular,
CD123+ PDC clusters are highly specific for CLE and
LEP in these contexts. Although CD123 immunohis-
tochemistry shows superior sensitivity and specificity
compared to most histopathological features exam-
ined in this study, it should be interpreted in
conjunction with clinical history, histopathological
examination, other immunohistochemical findings
and gene rearrangement studies (when necessary) to
ensure accurate diagnosis.
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